CRC chemoprevention in UC: mesalamine or thiopurine
In patients with UC of 15 years' duration with moderate activity and no dysplasia, is mesalamine chemoprevention or adding a thiopurine preferred for CRC risk reduction
What is known
- Guidelines (ECCO, BSG, Japanese Society of Gastroenterology) recommend 5-ASA for chemoprevention; the recommendation was strong but evidence moderate-to-low quality. 1,2
- ECCO states there is insufficient evidence to recommend for or against thiopurine chemoprevention. 1,2
- In the CESAME cohort, thiopurines reduced CRC/high-grade dysplasia risk in long-term extensive colitis (HR 0.28), but were linked to increased lymphoproliferative malignancy. 2
- Thiopurine protective effects vary by region and disease type, with no significant effect in some meta-analyses and case-control studies. 2–4
What is unknown / caveats
- Thiopurine studies show protection in some cohorts but no effect in several meta-analyses/case-control studies
- One 5-ASA pooled analysis showed protection, a later nonreferral systematic review did not
- No head-to-head mesalamine vs thiopurine comparison in the excerpts
- Chemoprevention data are observational; an RCT is considered unfeasible/unethical
- Excerpts do not address combining or sequencing the two agents
- The excerpts do not compare the two agents directly, so relative preference for CRC prevention in this patient cannot be determined.
References
- Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P, Langner C, Limdi JK, Pellino G, Zagórowicz E, Raine T, Harbord M, Rieder F, European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017;11:649-670. PMID: 28158501.
- Hsiao SW, Yen HH, Chen YY. Chemoprevention of Colitis-Associated Dysplasia or Cancer in Inflammatory Bowel Disease. Gut Liver. 2022. PMID: 35670121.
- Dan WY, Zhou GZ, Peng LH, Pan F. Update and latest advances in mechanisms and management of colitis-associated colorectal cancer. World J Gastrointest Oncol. 2023;15(8):1317-1331. PMID: 37663937.
- Sengupta, Neil, Yee, Eric, Feuerstein, Joseph D. Colorectal Cancer Screening in Inflammatory Bowel Disease. Dig Dis Sci. 2016;61:980-9. PMID: 26646250.
For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.
⚠ Required context not in this corpus (moderate). SCENIC consensus (Laine 2015, PMID 25708752): dysplasia surveillance in colonic IBD uses high-definition colonoscopy with chromoendoscopy and TARGETED biopsy of visible lesions, and a completely endoscopically resected visible dysplastic lesion is followed by surveillance rather than reflex colectomy.
Why this matters: Advising colectomy for an endoscopically resectable visible dysplastic lesion, or describing random-biopsy-only surveillance as current practice, can commit a patient to an avoidable proctocolectomy.
Added by the landmark interlock. This corpus is surgical in scope and cannot admit the source paper (PMID 25708752). Not generated by the RAG.
Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct.
Reviewer notes